Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VTX-27 is a selective inhibitor of protein kinase C θ (PKC θ) (Kis: 0.08 nM and 16 nM for PKC θ and PKC δ).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 143.00 | |
2 mg | In stock | $ 213.00 | |
5 mg | In stock | $ 428.00 | |
10 mg | In stock | $ 639.00 | |
25 mg | In stock | $ 987.00 | |
50 mg | In stock | $ 1,370.00 | |
100 mg | In stock | $ 1,830.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 396.00 |
Description | VTX-27 is a selective inhibitor of protein kinase C θ (PKC θ) (Kis: 0.08 nM and 16 nM for PKC θ and PKC δ). |
Targets&IC50 | PKCα:356 nM (ki), PKCδ:16 nM (ki), PKCθ:0.08 nM (ki) |
In vitro | It has also been found that VTX-27 has good selectivity to other PKC family members, especially the classic isoforms (except for PKCβI, >1000 times, 200 times) and atypical isoforms (>10000 times). As expected, it is more challenging to obtain selectivity for more closely related novel PKC family members, which is 200 times more selective than PKCδ. |
In vivo | VTX-27 shows the best PK profile with low clearance (7 mL/min/kg), good oral bioavailability (65%), and long half-life (4.7 h). A single dose of VTX-27 is administered orally at 6.25, 12.5, 25, and 50 mg/kg (e.g., at 25 mg/kg Cmax concentration 700 ng/mL) and demonstrates potent dose-dependent inhibition of IL-2 production. |
Molecular Weight | 418.9 |
Formula | C20H24ClFN6O |
CAS No. | 1321924-70-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (298.40 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VTX-27 1321924-70-2 Chromatin/Epigenetic Cytoskeletal Signaling PKC Inhibitor VTX 27 Protein kinase C inhibit VTX27 inhibitor